Xponance Inc. Buys 5,758 Shares of Cencora, Inc. (NYSE:COR)

Xponance Inc. raised its holdings in shares of Cencora, Inc. (NYSE:COR - Free Report) by 9.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 68,295 shares of the company's stock after acquiring an additional 5,758 shares during the quarter. Xponance Inc.'s holdings in Cencora were worth $15,345,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of COR. State Street Corp lifted its holdings in shares of Cencora by 3.8% during the 3rd quarter. State Street Corp now owns 8,045,896 shares of the company's stock valued at $1,810,970,000 after buying an additional 291,867 shares during the last quarter. Wellington Management Group LLP lifted its holdings in shares of Cencora by 7.0% during the 3rd quarter. Wellington Management Group LLP now owns 5,193,386 shares of the company's stock valued at $1,168,927,000 after buying an additional 338,452 shares during the last quarter. Boston Partners lifted its holdings in shares of Cencora by 2.6% during the 4th quarter. Boston Partners now owns 5,007,100 shares of the company's stock valued at $1,128,058,000 after buying an additional 125,611 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Cencora by 4.7% during the 3rd quarter. Geode Capital Management LLC now owns 4,195,851 shares of the company's stock valued at $941,183,000 after buying an additional 189,054 shares during the last quarter. Finally, Pacer Advisors Inc. lifted its holdings in shares of Cencora by 6.7% during the 4th quarter. Pacer Advisors Inc. now owns 2,204,242 shares of the company's stock valued at $495,249,000 after buying an additional 138,868 shares during the last quarter. Hedge funds and other institutional investors own 97.52% of the company's stock.

Remove Ads

Insider Activity

In other news, EVP Silvana Battaglia sold 5,000 shares of the business's stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the sale, the executive vice president now directly owns 15,374 shares in the company, valued at approximately $3,724,197.76. The trade was a 24.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Robert P. Mauch sold 4,970 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $255.00, for a total value of $1,267,350.00. Following the sale, the chief executive officer now owns 51,070 shares in the company, valued at approximately $13,022,850. This represents a 8.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 11,970 shares of company stock worth $2,998,670. Company insiders own 10.80% of the company's stock.

Wall Street Analyst Weigh In

COR has been the subject of several research reports. StockNews.com upgraded Cencora from a "hold" rating to a "buy" rating in a report on Wednesday, March 12th. Wells Fargo & Company lifted their price target on Cencora from $251.00 to $274.00 and gave the company an "equal weight" rating in a report on Friday, March 14th. Evercore ISI boosted their target price on Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a report on Thursday, February 6th. JPMorgan Chase & Co. boosted their target price on Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a report on Friday, January 24th. Finally, Mizuho began coverage on Cencora in a report on Wednesday, December 4th. They issued an "outperform" rating and a $280.00 target price for the company. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, Cencora has an average rating of "Moderate Buy" and an average target price of $280.20.

Cencora Stock Performance

Shares of COR stock traded down $0.93 during trading hours on Friday, reaching $266.91. 6,526,576 shares of the company's stock were exchanged, compared to its average volume of 1,379,194. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $271.08. The stock has a market capitalization of $51.76 billion, a P/E ratio of 37.97, a P/E/G ratio of 1.31 and a beta of 0.51. The business has a fifty day moving average price of $250.62 and a 200-day moving average price of $240.03. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40.

Cencora (NYSE:COR - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, topping analysts' consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Analysts predict that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Friday, February 14th were given a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.82%. The ex-dividend date was Friday, February 14th. Cencora's dividend payout ratio is presently 31.29%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.